(Photo Courtesy: www.csfme.org)
The global treatment market for peripheral artery disease (PAD) will expand in value from approximately $543.4 million in 2014 to a peak of $983.6 million in 2020, before falling to $816.3 million by 2024 due to the generic erosion of Brilinta and Xarelto, according to research and consulting firm GlobalData.
The company's latest report states that the initial dramatic increase in the value of the overall global PAD therapeutics space, which covers the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK, Japan, and urban China, will be partly attributable to the launch of several highly promising PAD drugs currently in late-stage pipeline development.
Mr Shaan Thakerar, GlobalData's senior analyst covering cardiovascular and metabolic disorders, says three novel antithrombotic pharmacological agents, namely Merck & Co's Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's Xarelto (rivaroxaban), all have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
Mr Thakerar comments: "The antithrombotic agents Xarelto, Zontivity, and Brilinta will bring new drug targets and novel mechanisms of action to the arsenal of long-term blood-thinning treatment strategies.
"The unveiling of Xarelto into the anticoagulant therapeutics space for PAD will mark the biggest step forward in the anticoagulant market since warfarin, but will come without the liabilities of its first-generation predecessor."